Non-invasive Detection of IDH-mutant Gliomas using Single and Multi-voxel Point-resolved Spectroscopy

Le résumé fourni par la source

IDH mutation has become one of the most important prognostic biomarkers in glioma management, regardless of histopathological features. The oncometabolite 2HG has been proposed as a biomarker for IDH-specific genetic profiles for gliomas. We report clinical utility of SVS and 1H-MRSI using a long TE (97 ms) in assessing IDH-mutant gliomas by detecting the characteristic resonances of 2HG. Our results from 25 patients showed sensitivity and specificity of 77% and 83%, respectively. In conclusion, 1H-MRS with optimized TE can accurately detect 2HG levels, which has significant clinical implications for determining prognosis and evaluating therapeutic efficacy for targeted and/or alternative therapies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.